Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-CD20 bispecific antibody DR-0201

A bispecific monoclonal antibody that targets the human tumor-associated antigen (TAA) CD20, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD20 bispecific antibody DR-0201 targets and binds to CD20 on B-cell surface. This results in CD20-mediated signaling blockade and may induce phagocytosis of CD20-overexpressing cells by tissue-resident and trafficking myeloid cells, such as macrophages. This results in a depletion of pathogenic B cells. CD20 is overexpressed by certain cancer cell types and in various autoimmune diseases.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:bispecific myeloid cell engager DR-0201
MCE DR-0201
Code name:DR 0201
DR-0201
DR0201
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search